Biotechs End 2016 IPO Drought With $252.8M Total Pricing
Stock in genome editing company Editas Medicine Inc. and cancer treatment developer Beigene Ltd. was trading well above announced prices Wednesday following their respective initial public offerings, the first such debuts...To view the full article, register now.
Already a subscriber? Click here to view full article